Множественная миелома (в комбинации с дексаметазоном) у пациентов, которые получили, по крайней мере, одну линию терапии.

LENALIDOMIDE

Revlimid is indicated for:Previously untreated multiple myeloma (MM) in adult patients who are not eligible for transplant .In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.Patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.Patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.